Resveratrol regulates gene transcription via activation of stimulus-responsive transcription factors

Pharmacological Research

Volumn 117, Issue , 2017, Pages 166-176

  Thiel, Gerald ^a   Rössler, Oliver G ^a  

^a SAARLAND UNIVERSITY   (Germany)

Author keywords

AP 1; c Fos; c Jun; CREB; Elk 1; Nrf2; Resveratrol; SIRT1

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR 2; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; EARLY GROWTH RESPONSE FACTOR 1; PROTEIN C JUN; RESVERATROL; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR AP 1; TRANSCRIPTION FACTOR ELK 1; TRANSCRIPTION FACTOR NRF2; STILBENE DERIVATIVE;

ANTIINFLAMMATORY ACTIVITY; BINDING SITE; DRUG MECHANISM; ENZYME ACTIVATION; EPIGENETICS; GENE CONTROL; GENE EXPRESSION; GENETIC ASSOCIATION; HUMAN; IMMEDIATE EARLY GENE; INTRACELLULAR SIGNALING; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DNA BINDING; PROTEIN PHOSPHORYLATION; REVIEW; TRANSCRIPTION INITIATION; TRANSCRIPTION REGULATION; UPREGULATION; ANIMAL; DRUG EFFECTS; GENETIC TRANSCRIPTION; METABOLISM; SIGNAL TRANSDUCTION;

ANIMALS; HUMANS; SIGNAL TRANSDUCTION; STILBENES; TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC; TRANSCRIPTIONAL ACTIVATION;

EID: 85007330176     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2016.12.029     Document Type: Review

References (113)

1. [1] Weiskirchen, S., Weiskirchen, R., Resveratrol: how much wine do you have to drink to stay healthy?. Adv. Nutr. 7 (2016), 706–718.
2. [2] Jang, M., Cai, L., Udeani, G.O., Slowing, K.V., Thomas, C.F., Beecher, C.W., Fong, H.H., Farnsworth, N.R., Kinghorn, A.D., Mehta, R.G., Moon, R.C., Pezzuto, J.M., Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 275 (1997), 218–220.
3. [3] Bhat, K.P.L., Kosmeder 2nd, J.W., Pezzuto, J.M., Biological effects of resveratrol. Antioxid. Redox Signal. 3 (2001), 1041–1064.
4. [4] Aggarwal, B.B., Bhardwaj, A., Aggarwal, R.S., Seeram, N.P., Shishodia, S., Takada, Y., Role of resveratrol in prevention and therapy of cancer: preclinical and clinical studies. Anticancer Res. 24 (2004), 2783–2840.
5. [5] Baur, J.A., Sinclair, D.A., Therapeutic potential of resveratrol: the in vivo evidence. Nat. Rev. Drug Discov. 5 (2006), 493–506.
6. [6] Jang, M., Cai, L., Udeani, G.O., Slowing, K.V., Thomas, C.F., Beecher, C.W., Fong, H.H., Farnsworth, N.R., Kinghorn, A.D., Metha, R.G., Moon, R.C., Pezzuto, J.M., Cancer chemopreventive activity of resveratrol. Science 275 (1997), 218–220.
7. [7] Park, E.-J., Pezzuto, J.M., The pharmacology of resveratrol in animals and humans. Biochim. Biophys. Acat A 1852 (2015), 1071–1113.
8. [8] Kodali, M., Parihar, V.K., Hattiangady, B., Mishra, V., Shuai, B., Shetty, A.K., Resveratrol prevents age-related memory and mood dysfunction with increased hippocampal neurogenesis and microvasculature, and reduced glial activation. Sci. Rep., 5, 2015, 8075.
9. [9] Smoliga, J.M., Baur, J.A., Hausenblas, H.A., Resveratrol and health −A comprehensive review of human clinical trials. Mol. Nutr. Food. Res. 55 (2011), 1129–1141.
10. [10] Novelle, M.G., Wahl, D., Diéguez, C., Bernier, M., de Cabo, R., Resveratrol supplementation: where are we now and where should we go?. Ageing. Res. Rev. 21 (2015), 1–15.
11. [11] Bastianetto, S., Ménard, C., Quirion, R., Neuroprotective action of resveratrol. Biochim. Biophys. Acta 1852 (2015), 1195–1201.
12. [12] Poulsen, M.M., Fjeldborg, K., Ornstrup, M.J., Kjaer, T.N., Nohr, M.K., Pedersen, S.B., Resveratrol and inflammation: challenges in translating pre-clinical findings to improve patient outcomes. Biochim. Biophys. Acta 1852 (2015), 1124–1136.
13. [13] Bonnefont-Rousselot, D., Resveratrol and cardiovascular diseases. Nutrients, 8, 2016, pii: E250, 10.3390/nu8050250.
14. [14] Cottart, C.-H., Nivet-Antoine, V., Beaudeux, J.-L., Review of recent data on the metabolism biological effects, and toxicity of resveratrol in humans. Mol. Nutr. Food Res. 58 (2014), 7–21.
15. [15] Tang, P.C.-T., Ng, Y.-F., Ho, S., Gyda, M., Chan, S.-W., Resveratrol and cardiovascular health −Promising therapeutic or hopeless illusion. Pharmacol. Res. 90 (2014), 88–115.
16. [16] Athar, M., Back, J.H., Kopelovich, L., Bickers, D.R., Kim, A.L., Multiple molecular targets of resveratrol: anti-carcinogenic mechanisms. Arch. Biochem. Biophys. 486 (2009), 95–102.
17. [17] Whitlock, N.C., Baek, S.J., The anticancer effects of resveratrol −modulation of transcription factors. Nutr. Cancer 64 (2012), 493–502.
18. [18] Avraham, R., Yarden, Y., Feedback regulation of EGFR signalling: decision making by early and delayed loops. Nat. Rev. Mol. Cell Biol. 12 (2011), 104–117.
19. [19] Nakata, R., Takahashi, S., Inoue, H., Recent advances in the study of resveratrol. Biol. Pharm. Bull. 35 (2012), 273–279.
20. [20] Russo, M.W., Sevetson, B.R., Milbrandt, J., Identification of NAB1, a repressor of NGFI-A and Krox20-mediated transcripton. Proc. Natl. Acad. Sci. USA 92 (1995), 6873–6877.
21. [21] Svaren, J., Sevetson, B.R., Apel, E.D., Zimonjic, D.B., Popescu, N.C., Milbrandt, J., NAB2 a corepressor of NGFI-A (egr-1) and Krox20, is induced by proliferative and differentiative stimuli. Mol. Cell. Biol. 16 (1996), 3545–3553.
22. [22] Thiel, G., Kaufmann, K., Magin, A., Lietz, M., Bach, K., Cramer, M., The human transcriptional repressor protein NAB1: expression and biological activity. Biochim. Biophys. Acta 1493 (2000), 289–301.
23. [23] Zhang, X., Odom, D.T., Koo, S.H., Conkright, M.D., Canettieri, G., Best, J., Chen, H., Jenner, R., Herbolsheimer, E., Jacobsen, E., Kadam, S., Ecker, J.R., Emerson, B., Hogenesch, J.B., Unterman, T., Young, R.A., Montminy, M., Genome-wide analysis of cAMP-response element binding protein occupancy, phosphorylation, and target gene activation in human tissues. Proc. Natl. Acad. Sci. U. S. A. 102 (2005), 4459–4464.
24. 2+-activated, CREB-dependent transcription in astrocytes. Glia 57 (2009), 828–834.
25. [25] Karin, M., The regulation of AP-1 activity by mitogen-activated protein kinases. J. Biol. Chem. 270 (1995), 16483–16486.
26. [26] Rubil, S., Rössler, O.G., Thiel, G., CREB, AP-1, ternary complex factors and MAP kinases connect transient receptor potential melastatin-3 (TRPM3) channel stimulation with increased c-Fos expression. Brit. J. Pharmacol. 173 (2016), 305–318.
27. [27] Ely, H.A., Mellon, P.L., Coss, D., GnRH induces the c-Fos gene via phosphorylation of SRF by the calcium/calmodulin kinase II pathway. Mol. Endocrinol 25 (2011), 669–680.
28. [28] Cha-Molstad, H., Keller, D.M., Yochum, G.S., Impey, S., Goodman, R.H., Cell-type-specific binding of the transcription factor CREB to the cAMP-response element. Proc. Natl. Acad. Sci. U. S. A. 101 (2004), 13572–13577.
29. [29] Tur, G., Geogieva, E.I., Gagete, A., López-Rodas, G., Rodriguez, J.L., Franco, L., Factor binding and chromatin modification in the promoter of murine Egr1 gene upon induction. Cell. Mol. Life Sci. 67 (2010), 4065–4077.
30. [30] Jeong, S., Stein, A., Micrococcal nuclease digestion of nuclei reveals extended nucleosome ladders having anomalous DNA lengths for chromatin assembled on non-replicating plasmids in transfected cells. Nucl. Acids Res. 22 (1994), 370–375.
31. [31] Smith, C.L., Hager, G.L., Transcriptional regulation of mammalian genes in vivo. J. Biol. Chem. 272 (1997), 27493–27496.
32. [32] Chiu, R., Boyle, W.J., Meek, J., Smeal, T., Hunter, T., Karin, M., The c-fos protein interacts with c-jun/AP-1 to stimulate transcription of AP-1 responsive genes. Cell 54 (1988), 541–552.
33. [33] Shaulian, E., Karin, M., AP-1 as a regulator of cell life and death. Nat. Cell Biol. 4 (2002), E131–E136.
34. [34] Johnson, R.S., Spiegelman, B.M., Papaionnou, V., Pleiotropic effects of a null mutation in the c-fos proto-oncogene. Cell 71 (1992), 577–586.
35. [35] Zhang, J., Zhang, D., McQuade, J.S., Behbehani, M., Tsien, J.Z., Xu, M., c-fos regulates neuronal excitability and survival. Nat. Genet. 30 (2002), 416–420.
36. [36] Morton, S., Davis, R.J., McLaren, A., Cohen, P., A reinvestigation of the multisite phosphorylation of the transcription factor c-Jun. EMBO J. 22 (2003), 3876–3886.
37. [37] Thiel, G., Rössler, O.G., Immediate-early transcriptional response to angiotensin II in human adrenocortical cells. Endocrinology 152 (2011), 4211–4223.
38. [38] Johnson, R.S., Van Lingen, B., Papaioannou, V.E., Spiegelman, B.M., A null mutation of the c-jun locus causes embryonic lethality and retarded cell growth in culture. Genes Dev. 7 (1993), 1309–1317.
39. [39] Livingstone, C., Patel, G., Jones, N., ATF-2 contains a phosphorylation-dependent transcriptional activation domain. EMBO J. 14 (1995), 1785–1797.
40. [40] Maekawa, T., Bernier, F., Sato, M., Nomura, S., Singh, M., Inoue, Y., Tokunaga, T., Imai, H., Yokoyama, M., Reimold, A., Glimcher, L.H., Ishii, S., Mouse ATF-2 null mutants display features of a severe type of meconium aspiration syndrome. J. Biol. Chem. 274 (1999), 17813–17819.
41. [41] Maekawa, T., Shinagawa, T., Sano, Y., Sakuma, T., Nomura, S., Nagasaki, K., Miki, Y., Saito-Ohara, F., Inazawa, J., Kohno, T., Yokota, J., Ishii, S., Reduced levels of ATF-2 predispose mice to mammary tumors. Mol. Cell. Biol. 27 (2007), 1730–1744.
42. [42] Gozdecka, M., Lyons, S., Kondo, S., Taylor, J., Li, Y., Walczynski, J., Thiel, G., Breitwieser, W., Jones, N., JNK suppresses tumor formation via a gene-expression program mediated by ATF2. Cell Rep. 9 (2014), 1361–1374.
43. [43] Manna, S.K., Mukhopadhyay, A., Aggarwal, B.B., Resveratrol suppresses TNF-induced activation of nuclear transcription factor NF-κB, activator protein-1, and apoptosis: potential role of reactive oxygen intermediates and lipid peroxidation. J. Immunol. 164 (2000), 6509–6519.
44. [44] Yu, R., Hebbar, V., Kim, D.W., Mandlekar, S., Pezzuto, J.M., Kong, A.N., Resveratrol inhibits phorbol ester and UV-induced activator protein 1 activation by interfering with mitogen-activated protein kinase pathways. Mol. Pharmacol. 60 (2001), 217–224.
45. [45] Kundu, J.K., Shin, Y.K., Surh, Y.J., Resveratrol modulates phorbol ester-induced pro-inflammatory signal transduction pathways in mouse skin in vivo, NF-κB and AP-1 as prime targets. Biochem. Pharmacol. 72 (2006), 1506–1515.
46. [46] Kubota, S., Kurihara, T., Ebinuma, M., Kubota, M., Yuki, K., Sasaki, M., Noda, K., Ozawa, Y., Oike, Y., Ishida, S., Tsubota, K., Resveratrol prevents light-induced retinal degeneration via suppressing activator protein-1 activation. Am. J. Pathol. 177 (2010), 1725–1731.
47. [47] Thiel, G., Rössler, O.G., Resveratrol stimulates AP-1-regulated gene transcription. Mol. Nutr. Food Res. 58 (2014), 1402–1413.
48. 2+ concentration, phosphorylation of ERK and activation of ternary complex factor. BMC Mol. Biol., 10, 2009, 40.
49. [49] Thiel, G., Lesch, A., Keim, A., Transcriptional response to calcium-sensing receptor stimulation. Endocrinology 153 (2012), 4716–4728.
50. [50] Kaufmann, A., Keim, A., Thiel, G., Regulation of immediate-early gene transcription following activation of Gαq-coupled designer receptors. J. Cell. Biochem. 114 (2013), 681–696.
51. [51] Hsu, S.-C., Huang, S.-M., Chen, A., Sun, C.-Y., Lin, S.-H., Chen, J.-S., Liu, S.-T., Hsu, Y.-J., Resveratrol increases anti-aging Klotho gene expression via the activating transcription factor 3/c-Jun complex-mediated signaling pathway. Int. J. Biochem. Cell Biol. 53 (2014), 361–371.
52. [52] Thiel, G., Rössler, O.G., Resveratrol stimulates cyclic AMP response element-mediated gene transcription. Mol. Nutr. Food Res. 60 (2016), 256–265.
53. [53] Johannessen, M., Delghandi, M.P., Moens, U., What turns CREB on?. Cell. Signal. 16 (2004), 1211–1227.
54. [54] Barco, A., Kandel, E.R., The role of CREB and CBP in brain function. Thiel, G., (eds.) Transcription Factors in the Nervous System −Development, Brain Function, and Diseases, 2006, Wiley-VCH Verlag, Weinheim, 207–241.
55. [55] Mayr, B., Montminy, M., Transcriptional regulation by the phosphorylation-dependent factor CREB. Nat. Rev. Mol. Cell Biol. 2 (2001), 599–609.
56. [56] Park, S.J., Ahmad, F., Philp, A., Baar, K., Williams, T., Luo, H., Ke, H., Rehmann, H., Taussig, R., Brown, A.L., Kim, M.K., Beaven, M.A., Burgin, A.B., Manganiello, V., Chung, J.H., Resveratrol ameliorates aging-related metabolic phenotypes by inhibiting cAMP phosphodiesterases. Cell 148 (2012), 421–433.
57. [57] Andrews, C.A., Matsuyama, S., Lee, B.-C., Li, J.-D., Resveratrol suppresses NTHi-induced inflammation via upregulation of the negative regulator MyD88 short. Sci. Rep., 6, 2016, 34445, 10.1038/srep34445.
58. [58] Riccio, A., Ahn, S., Davenport, C.M., Blendy, J.A., Ginty, D.D., Mediation by a CREB family transcription factor of NGF-dependent survival of sympathetic neurons. Science 286 (1999), 2358–2361.
59. [59] Park, H.R., Kong, K.H., Yu, B.P., Mattson, M.P., Lee, J., Resveratrol inhibits the proliferation of neural progenitor cells and hippocampal neurogenesis. J. Biol. Chem. 287 (2012), 42588–42600.
60. [60] Simao, F., Matté, A., Pagnussat, A.S., Netto, C.A., Salbego, C.G., Resveratrol prevents CA1 neurons against ischemic injury by parallel modulation of both GSK-3β and CREB through PI3-K/Akt pathways. Eur. J. Neurosci. 36 (2012), 2899–2905.
61. [61] Li, Z., Fang, F., Wang, Y., Wang, L., Resveratrol protects CA1 neurons against focal cerbral ischemic reperfusion-induced damage via the ERK-CREB signaling pathway in rats. Pharmacol. Biochem. Behav. 146–147 (2016), 21–27.
62. [62] Xie, B., Wang, C., Zheng, Z., Song, B., Ma, C., Thiel, G., Li, M., Egr-1 transactivates Bim gene expression to promote neuronal apoptosis. J. Neurosci. 31 (2011), 5032–5044.
63. [63] Wei, F., Xu, Z.C., Qu, Z., Milbrandt, J., Zhuo, M., Role of EGR1 in hippocampal synaptic enhancement induced by tetanic stimulation and amputation. J. Cell. Biol. 149 (2000), 1325–1333.
64. [64] Mayer, S.I., Rössler, O.G., Endo, T., Charnay, P., Thiel, G., Epidermal growth factor-induced proliferation of astrocytes requires Egr transcription factors. J. Cell Sci. 122 (2009), 3340–3350.
65. [65] Lee, S., Sadovsky, Y., Swirnoff, A.H., Polish, J.A., Goda, P., Gavrilina, G., Milbrandt, J., Luteinizing hormone deficiency and female infertility in mice lacking the transcription factor NGFI-A (egr-1). Science 273 (1996), 1219–1221.
66. [66] Yan, S.F., Fujita, T., Lu, J., Okada, K., Shan Zou, Y., Mackman, N., Pinsky, D.J., Stern, D.M., Egr-1, a master switch coordinating upregulation of divergent gene families underlying ischemic stress. Nat. Med. 6 (2000), 1355–1361.
67. [67] Müller, I., Rössler, O.G., Wittig, C., Menger, M.D., Thiel, G., Critical role of Egr transcription factors in regulating insulin biosynthesis, blood glucose homeostasis and islet size. Endocrinology 153 (2012), 3040–3053.
68. [68] Bickenbach, K.A., Veerapong, J., Shao, M.Y., Mauceri, H.J., Posner, M.C., Kron, S.J., Weichselbaum, R.R., Resveratrol is an effective inducer of CArG-driven TNF-alpha gene therapy. Cancer Gene Ther. 15 (2008), 133–139.
69. [69] Whitlock, N.C., Bahn, J.H., Lee, S.-H., Eling, T.E., Baek, S.J., Resveratrol-induced apoptosis is mediated by early growth response-1 Krüppel-like factor 4, and activating transcription factor 3. Cancer Prev. Res. 4 (2011), 116–127.
70. [70] Shi, Q., Geldenhuys, W., Sutariya, V., Bishayee, A., Patel, I., Bhatia, D., CArG-driven GADD45α activated by resveratrol inhibits lung cancer cells. Genes Cancer 6 (2015), 220–230.
71. [71] Ragione, F.D., Cucciolla, V., Criniti, V., Indaco, S., Borriello, A., Zappia, V., p21Cip1gene expression is modulated by Egr1: a novel regulatory mechanism involved in the resveratrol antiproliferative effect. J. Biol. Chem. 278 (2003), 23360–23368.
72. [72] Utreras, U., Terse, A., Keller, A., Iadarola, M.J., Kulkarni, A.B., Resveratrol inhibits Cdk5 activity through regulation of p35 expression. Mol. Pain, 7, 2011, 49.
73. [73] Rössler, O.G., Glatzel, D., Thiel, G., Resveratrol upregulates Egr-1 expression and activity involving extracellular signal-regulated protein kinase and ternary complex factors. Exp. Cell. Res. 332 (2015), 116–127.
74. [74] Müller, I., Endo, T., Thiel, G., Regulation of AP-1 activity in glucose-stimulated insulinoma cells. J. Cell. Biochem. 110 (2010), 1481–1494.
75. 2+ ions and the transcription factors c-Jun ATF2, and ternary complex factor. Mol. Pharmacol. 87 (2015), 617–628.
76. [76] Baird, L., Dinkova-Kostova, A.T., The cytoprotective role of the Keap1-Nrf2 pathway. Arch. Toxicol. 85 (2011), 241–272.
77. [77] Sporn, M.B., Liby, K.T., NRF2 and cancer: the good, the bad and the importance of context. Nat. Rev. Cancer 12 (2012), 564–571.
78. [78] Chen, C.-Y., Jang, J.-H., Li, M.-H., Surh, Y.-J., Resveratrol upregulates heme oxygenase-1 expression of NF-E2-related factor 2 in PC12 cells. Biochem. Biophys. Res. Comm. 331 (2005), 993–1000.
79. [79] He, X., Wang, L., Szklarz, G., Bi, Y., Ma, Q., Resveratrol inhibits paraquat-induced oxidative stress and fibrogenic response by activating the nuclear factor eryrythroid 2-related factor 2 pathway. J. Pharmacol. Exp. Therap. 342 (2012), 81–90.
80. 2 semiquinones, and quinones. Free Radic. Biol. Med. 51 (2011), 2319–2327.
81. [81] Balstad, T.R., Carlsen, H., Myhrstad, M.C.W., Kolberg, M., Reiersen, H., Gilen, L., Ebihara, K., Paul, I., Blomhoff, R., Coffee, broccoli and spices are strong inducers of electrophile response-element-dependent transcription in vitro and in vivo −studies in electrophile response element transgenic mice. Mol. Nutr. Food Res. 55 (2011), 185–197.
82. [82] Kode, A., Rajendrasozhan, S., Caito, S., Yang, S.R., Megson, I.L., Rahman, I., Resveratrol induces glutathione synthesis by activation of Nrf2 and protects against cigarette smoke-mediated oxidative stress in human lung epithelial cells. Am. J. Physiol. −Lung Cell. Mol. Physiol. 294 (2008), L478–L488.
83. [83] Rubiolo, J.A., Mithieux, G., Vega, F.V., Resveratrol protects primary rat hepatocytes against oxidative stress damage: activation of the Nrf2 transcription factor and augmented activities of antioxidant enzymes. Eur. J. Pharmacol. 591 (2008), 66–72.
84. [84] Chun, K.-S., Kundu, J., Kundu, J.K., Surh, Y.-J., Targeting Nrf2-Keap1 signaling for chemoprevention of skin carcinogenesis with bioactive phytochemicals. Tox. Lett. 229 (2014), 73–84.
85. [85] Ungvari, Z., Bagi, Z., Feher, A., Recchia, F.A., Sonntag, W.E., Pearson, K., de Cabo, R., Csiszar, A., Resveratrol confers endothelial protection via activation of the antioxidant transcription factor Nrf2. A. J. Physiol. Heart Circ. Physiol. 299 (2010), H18–H24.
86. [86] Zhou, Y., Wu, H., Zhao, M., Chang, C., Lu, Q., The Bach family of transcription factors: a comprehensive review. Clinic. Rev. Allerg. Immunol. 50 (2016), 345–356.
87. [87] Beher, D., Wu, J., Cumine, S., Kim, K.W., Lu, S.C., Atangan, L., Wang, M., Resveratrol is not a direct activator of SIRT1 enzyme activity. Chem. Biol. Drug Des. 74 (2009), 619–624.
88. [88] Pacholec, M., Bleasdale, J.E., Chrunyk, B., Cunningham, D., Flynn, D., Garofalo, R.S., Griffith, D., Griffor, M., Loulakis, P., Pabst, B., Qiu, X., Stockman, B., Thanabal, V., Varghese, A., Ward, J., Withka, J., Ahn, K., SRT1720, SRT2183 SRT1460, and resveratrol are not direct activators of SIRT1. J. Biol. Chem. 285 (2010), 8340–8351.
89. [89] Price, N.L., Gomes, A.P., Ling, A.J., Duarte, F.V., Martin-Montalvo, A., North, B.J., Agarwal, B., Ye, L., Ramadori, G., Teodoro, J.S., Hubbard, B.P., Varela, A.T., Davis, J.G., Varamini, B., Hafner, A., Moaddel, R., Rolo, A.P., Coppari, R., Palmeira, C.M., de Cabo, R., Baur, J.A., Sinclair, D.A., SIRT1 is required for AMPK activation and the beneficial effects of resveratrol on mitochondrial function. Cell Metabol. 15 (2012), 675–690.
90. [90] Coté, C.D., Rasmussen, B.A., Duca, F.A., Zadeh-Tahmasebi, M., Baur, J.A., Daljeet, M., Breen, D.M., Filippi, B.M., Lam, T.K., Resveratrol activates duodenal Sirt1 to reverse insulin resistance in rats through a neuronal network. Nat. Med. 21 (2015), 498–505.
91. [91] Monteserin-Garcia, J., Al-Massadi, Omar, Seoane, L.M., Alvarez, C.V., Shan, B., Stalla, J., Paez-Pereda, M., Casanueva, F.F., Stalla, G.K., Theodoropoulou, M., Sirt1 inhibits the transcription factor CREB to regulate pituitary growth hormone synthesis. FASEB J. 27 (2013), 1561–1571.
92. + metabolism and SIRT1 activity. Nature 458 (2009), 1056–1060.
93. [93] Um, J.-H., Park, S.-J., Kang, H., Yang, S., Foretz, M., McBurney, M.W., Kim, M.K., Violett, B., Chung, J.H., AMP-activated protein kinase-deficient mice are resistant to the metabolic effects of resveratrol. Diabetes 59 (2010), 554–563.
94. [94] Gao, Z., Ye, J., Inhibition of transcriptional activity of c-Jun by SIRT1. Biochem. Biophys. Res. Commun. 376 (2008), 793–796.
95. [95] Zhang, R., Chen, H.-Z., Liu, J.-J., Jia, Y.-Y., Zhang, Z.-Q., Yang, R.-F., Zhang, Y., Xu, J., Wei, Y.-S., Liu, D.-P., Liang, C.C., SIRT1 suppresses activator protein-1 transcriptional activity and cyclooxygenase-2 expression in macrophages. J. Biol. Chem. 285 (2010), 7097–7110.
96. [96] Kawai, Y., Garduno, L., Theodore, M., Yang, J., Arinze, I.J., Acetylation-deacetylation of the transcription factor Nrf2 (nuclear factor erythroid 2-related factor 2) regulates ist transcriptional activity and nucleocytoplasmic localization. J. Biol. Chem. 286 (2011), 7629–7640.
97. [97] Britton, R.G., Kovoor, C., Brown, K., Direct molecular targets of resveratrol: identifying key interactions to unlock complex mechanisms. Ann. N.Y. Acad. Sci 1348 (2015), 124–133.
98. [98] Narayanan, B.A., Narayanan, N.K., Stoner, G.D., Bullock, B.P., Interactive gene expression pattern in prostate cancer cells exposed to phenolic antioxidants. Life Sci. 70 (2002), 1821–1839.
99. [99] Vo, N., Goodman, R.H., CREB-binding protein and p300 in transcriptional regulation. J. Biol. Chem. 276 (2001), 13505–13508.
100. [100] Goldberg, D.M., Yan, J., Soleas, G.J., Absorption of three wine-related polyphenols in three different matrices by healthy subjects. Clin. Biochem. 36 (2003), 79–87.
101. [101] Meng, X., Maliakal, P., Lu, H., Lee, M.J., Yang, C.S., Urinary and plasma levels of resveratrol and quercetin in human, mice and rats after ingestion of pure compounds and grape juice. J. Agric. Food. Chem. 52 (2004), 935–942.
102. [102] Walle, T., Hsieh, F., DeLegge, M.H., Oatis, J.E. Jr., Walle, K., High absorption but very low bioavaiability of oral resveratrol in humans. Drug Metab. Dispos. 32 (2004), 1377–1382.
103. [103] Visioli, F., The resveratrol fiasco. Pharmacol. Res., 90, 2014, 87.
104. [104] Vang, O., Ahmad, N., Baile, C.A., Baur, J.A., Brown, K., Csiszar, A., Das, D.K., Delmas, D., Gottfried, C., Lin, H.-Y., Ma, Q.-Y., Mukhopadhyay, P., Nalini, N., Pezzuto, J.M., Richard, T., Shukla, Y., Surh, Y.-J., Szekeres, T., Szkudelski, T., Walle, T., Wu, J.M., What is new for an old molecule? Systematic review and recommendations on the use of resveratrol. PLoS One, 6, 2011, e19881.
105. [105] Kondratyuk, T.P., Park, E.-J., Marler, L.E., Ahn, S., Yuan, Y., Choi, Y., Yu, R., van Breemen, R.B., Sun, B., Hoshino, J., Cushman, M., Jermihov, K.C., Mesecar, A.D., Grubbs, C.J., Pezzuto, J.M., Resveratrol derivatives as promising chemopreventive agents with improved potency and selectivity. Mol. Nutr. Food Res. 55 (2011), 1249–1265.
106. [106] Mayhoub, A.S., Marler, L., Kondratyuk, T.P., Park, E.-J., Pezzuto, J.M., Cushman, M., Optimizing thiadiazole analogues of resveratrol versus three chemopreventive targets. Bioorg. Med. Chem. 20 (2012), 510–520.
107. [107] Mayhoub, A.S., Marler, L., Kondratyuk, T.P., Park, E.-J., Pezzuto, J.M., Cushman, M., Optimization of thiazole analogues of resveratrol for induction of NAD(P)H:quinone reductase 1 (QR1). Bioorganic Med. Chem. 20 (2012), 7030–7039.
108. [108] Johnson, J.J., Nihal, M., Siddiqui, I.A., Scarlett, C.O., Bailey, H.H., Mukhtar, H., Ahmad, N., Enhancing the bioavailability of resveratrol by combining it with piperine. Mol. Nutr. Foof Res. 55 (2011), 1169–1176.
109. [109] Amri, A., Chaumeil, J.C., Sfar, S., Charrueau, C., Administration of resveratrol: what formulation solution to biovaialability limitations?. J. Controlled Release 158 (2012), 182–193.
110. [110] Mattarei, A., Azzolini, M., La Soina, M., Zoratti, M., Paradidi, C., Biasutto, L., Amino acid carbamates as prodrugs of resveratrol. Sci. Rep., 5, 2015, 15216.
111. [111] Davidov-Pardo, G., McClements, D.J., Resveratrol encapsulation: designing delivery systems to overcome solubility, stability and bioavailability issues. Trends Food Sci. Technol. 38 (2014), 88–103.
112. [112] Pearson, K.J., Baur, J.A., Lewis, K.N., Peshkin, L., Price, N.L., Labinskyy, N., Swindell, W.R., Kamara, D., Minor, R.K., Perez, E., Jamieson, H.A., Zhang, Y., Dunn, S.R., Sharma, K., Pleshko, N., Woollett, L.A., Csiszar, A., Ikeno, Y., Le Couteur, D., Elliott, P.J., Becker, K.G., Navas, P., Ingram, D.K., Wolf, N.S., Ungvari, Z., Sinclair, D.A., de Cabo, R., Resveratrol delays age-related deterioration and mimics transcriptional aspects of dietary restriction without extending life span. Cell Metabol. 8 (2008), 157–168.
113. [113] Pastore, S., Lulli, D., Maurelli, R., Dellambra, E., De Luca, C., Korkina, L.G., Resveratrol induces long-lasting IL-8 expression and peculiar EGFR activation/distribution in human keratinocytes: mechanisms and implications for skin administration. PLoS One, 8, 2013, e59632.